Olaparib approved in the US (but not yet for prostate cancer)

On Friday this week the U.S. Food and Drug Administration approved a drug known as olaparib (Lynparza®) for the treatment of a very specific form of very late stage ovarian cancer. This may be of interest to some men with late-stage prostate cancer. … READ MORE …

Prostate cancer and prostate cancer-specific survival of men from breast cancer-prone families

An Australian research team has used data from 148 men from 1,423 families identified through the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab) to assess the risks associated with prostate cancer in males from breast cancer-prone families, and most particularly from those families in which the BRCA2 gene mutation is prevalent. … READ MORE …

Your Wednesday news summary: November 19, 2008

Today’s reports cover such items as:

  • Disparities in cancer mortality between blacks and whites in the USA
  • Body mass, body fat distribution, and risk for prostate cancer
  • Risk for cancer in male carriers of BRCA mutations
  • A five-SNP genetic marker set and prostate cancer risk
  • Final results of the atrasentan trial in non-metastatic, HRPC patients
  • Is a rising plasma PDGF level an indicator for docetaxel failure? … READ MORE …